{"pmid":32396922,"title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.","text":["Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.","An outbreak of a novel coronavirus, named SARS-CoV-2, causing respiratory disease and a ~2% case fatality rate started in Wuhan, China in December 2019(1,2). Following unprecedented global spread(3), the World Health Organization declared COVID-19 a pandemic on March 11, 2020. Although data on disease in humans are emerging at a steady pace, certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models, where repeated sampling and tissue collection is possible. Here, we show that SARS-CoV-2 causes respiratory disease in infected rhesus macaques, with disease lasting 8-16 days. Pulmonary infiltrates, a hallmark of human disease, were visible in lung radiographs. High viral loads were detected in swabs from the nose and throat of all animals as well as in bronchoalveolar lavages; in one animal we observed prolonged rectal shedding. Taken together, the rhesus macaque recapitulates moderate disease observed in the majority of human cases. The establishment of the rhesus macaque as a model of COVID-19 will increase our understanding of the pathogenesis of this disease and will aid development and testing of medical countermeasures.","Nature","Munster, Vincent J","Feldmann, Friederike","Williamson, Brandi N","van Doremalen, Neeltje","Perez-Perez, Lizzette","Schulz, Jonathan","Meade-White, Kimberly","Okumura, Atsushi","Callison, Julie","Brumbaugh, Beniah","Avanzato, Victoria A","Rosenke, Rebecca","Hanley, Patrick W","Saturday, Greg","Scott, Dana","Fischer, Elizabeth R","de Wit, Emmie","32396922"],"abstract":["An outbreak of a novel coronavirus, named SARS-CoV-2, causing respiratory disease and a ~2% case fatality rate started in Wuhan, China in December 2019(1,2). Following unprecedented global spread(3), the World Health Organization declared COVID-19 a pandemic on March 11, 2020. Although data on disease in humans are emerging at a steady pace, certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models, where repeated sampling and tissue collection is possible. Here, we show that SARS-CoV-2 causes respiratory disease in infected rhesus macaques, with disease lasting 8-16 days. Pulmonary infiltrates, a hallmark of human disease, were visible in lung radiographs. High viral loads were detected in swabs from the nose and throat of all animals as well as in bronchoalveolar lavages; in one animal we observed prolonged rectal shedding. Taken together, the rhesus macaque recapitulates moderate disease observed in the majority of human cases. The establishment of the rhesus macaque as a model of COVID-19 will increase our understanding of the pathogenesis of this disease and will aid development and testing of medical countermeasures."],"journal":"Nature","authors":["Munster, Vincent J","Feldmann, Friederike","Williamson, Brandi N","van Doremalen, Neeltje","Perez-Perez, Lizzette","Schulz, Jonathan","Meade-White, Kimberly","Okumura, Atsushi","Callison, Julie","Brumbaugh, Beniah","Avanzato, Victoria A","Rosenke, Rebecca","Hanley, Patrick W","Saturday, Greg","Scott, Dana","Fischer, Elizabeth R","de Wit, Emmie"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396922","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41586-020-2324-7","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666627827804405760,"score":9.490897,"similar":[{"pmid":32434946,"title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques.","text":["SARS-CoV-2 infection protects against rechallenge in rhesus macaques.","An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates.","Science","Chandrashekar, Abishek","Liu, Jinyan","Martinot, Amanda J","McMahan, Katherine","Mercado, Noe B","Peter, Lauren","Tostanoski, Lisa H","Yu, Jingyou","Maliga, Zoltan","Nekorchuk, Michael","Busman-Sahay, Kathleen","Terry, Margaret","Wrijil, Linda M","Ducat, Sarah","Martinez, David R","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Pessaint, Laurent","Van Ry, Alex","Greenhouse, Jack","Taylor, Tammy","Blade, Kelvin","Cook, Anthony","Finneyfrock, Brad","Brown, Renita","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Abbink, Peter","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kordana, Nicole","Li, Zhenfeng","Lifton, Michelle A","Mahrokhian, Shant H","Maxfield, Lori F","Nityanandam, Ramya","Nkolola, Joseph P","Schmidt, Aaron G","Miller, Andrew D","Baric, Ralph S","Alter, Galit","Sorger, Peter K","Estes, Jacob D","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H","32434946"],"abstract":["An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates."],"journal":"Science","authors":["Chandrashekar, Abishek","Liu, Jinyan","Martinot, Amanda J","McMahan, Katherine","Mercado, Noe B","Peter, Lauren","Tostanoski, Lisa H","Yu, Jingyou","Maliga, Zoltan","Nekorchuk, Michael","Busman-Sahay, Kathleen","Terry, Margaret","Wrijil, Linda M","Ducat, Sarah","Martinez, David R","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Pessaint, Laurent","Van Ry, Alex","Greenhouse, Jack","Taylor, Tammy","Blade, Kelvin","Cook, Anthony","Finneyfrock, Brad","Brown, Renita","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Abbink, Peter","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kordana, Nicole","Li, Zhenfeng","Lifton, Michelle A","Mahrokhian, Shant H","Maxfield, Lori F","Nityanandam, Ramya","Nkolola, Joseph P","Schmidt, Aaron G","Miller, Andrew D","Baric, Ralph S","Alter, Galit","Sorger, Peter K","Estes, Jacob D","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434946","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1126/science.abc4776","topics":["Mechanism"],"weight":1,"_version_":1667521393540988928,"score":482.21097},{"pmid":32434945,"title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","text":["DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.","Science","Yu, Jingyou","Tostanoski, Lisa H","Peter, Lauren","Mercado, Noe B","McMahan, Katherine","Mahrokhian, Shant H","Nkolola, Joseph P","Liu, Jinyan","Li, Zhenfeng","Chandrashekar, Abishek","Martinez, David R","Loos, Carolin","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Chen, Yuezhou","Zuiani, Adam","N Lelis, Felipe J","Travers, Meghan","Habibi, Shaghayegh","Pessaint, Laurent","Van Ry, Alex","Blade, Kelvin","Brown, Renita","Cook, Anthony","Finneyfrock, Brad","Dodson, Alan","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kirilova, Marinela","Kordana, Nicole","Lin, Zijin","Maxfield, Lori F","Nampanya, Felix","Nityanandam, Ramya","Ventura, John D","Wan, Huahua","Cai, Yongfei","Chen, Bing","Schmidt, Aaron G","Wesemann, Duane R","Baric, Ralph S","Alter, Galit","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H","32434945"],"abstract":["The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates."],"journal":"Science","authors":["Yu, Jingyou","Tostanoski, Lisa H","Peter, Lauren","Mercado, Noe B","McMahan, Katherine","Mahrokhian, Shant H","Nkolola, Joseph P","Liu, Jinyan","Li, Zhenfeng","Chandrashekar, Abishek","Martinez, David R","Loos, Carolin","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Chen, Yuezhou","Zuiani, Adam","N Lelis, Felipe J","Travers, Meghan","Habibi, Shaghayegh","Pessaint, Laurent","Van Ry, Alex","Blade, Kelvin","Brown, Renita","Cook, Anthony","Finneyfrock, Brad","Dodson, Alan","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kirilova, Marinela","Kordana, Nicole","Lin, Zijin","Maxfield, Lori F","Nampanya, Felix","Nityanandam, Ramya","Ventura, John D","Wan, Huahua","Cai, Yongfei","Chen, Bing","Schmidt, Aaron G","Wesemann, Duane R","Baric, Ralph S","Alter, Galit","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434945","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1126/science.abc6284","topics":["Treatment"],"weight":1,"_version_":1667521393700372481,"score":463.90894},{"pmid":32318665,"pmcid":"PMC7167234","title":"Age-related rhesus macaque models of COVID-19.","text":["Age-related rhesus macaque models of COVID-19.","Background: Since December 2019, an outbreak of the Corona Virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Wuhan, China, has become a public health emergency of international concern. The high fatality of aged cases caused by SARS-CoV-2 was a need to explore the possible age-related phenomena with non-human primate models. Methods: Three 3-5 years old and two 15 years old rhesus macaques were intratracheally infected with SARS-CoV-2, and then analyzed by clinical signs, viral replication, chest X-ray, histopathological changes and immune response. Results: Viral replication of nasopharyngeal swabs, anal swabs and lung in old monkeys was more active than that in young monkeys for 14 days after SARS-CoV-2 challenge. Monkeys developed typical interstitial pneumonia characterized by thickened alveolar septum accompanied with inflammation and edema, notably, old monkeys exhibited diffuse severe interstitial pneumonia. Viral antigens were detected mainly in alveolar epithelial cells and macrophages. Conclusion: SARS-CoV-2 caused more severe interstitial pneumonia in old monkeys than that in young monkeys. Rhesus macaque models infected with SARS-CoV-2 provided insight into the pathogenic mechanism and facilitated the development of vaccines and therapeutics against SARS-CoV-2 infection.","Animal Model Exp Med","Yu, Pin","Qi, Feifei","Xu, Yanfeng","Li, Fengdi","Liu, Peipei","Liu, Jiayi","Bao, Linlin","Deng, Wei","Gao, Hong","Xiang, Zhiguang","Xiao, Chong","Lv, Qi","Gong, Shuran","Liu, Jiangning","Song, Zhiqi","Qu, Yajin","Xue, Jing","Wei, Qiang","Liu, Mingya","Wang, Guanpeng","Wang, Shunyi","Yu, Haisheng","Liu, Xing","Huang, Baoying","Wang, Wenling","Zhao, Li","Wang, Huijuan","Ye, Fei","Zhou, Weimin","Zhen, Wei","Han, Jun","Wu, Guizhen","Jin, Qi","Wang, Jianwei","Tan, Wenjie","Qin, Chuan","32318665"],"abstract":["Background: Since December 2019, an outbreak of the Corona Virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Wuhan, China, has become a public health emergency of international concern. The high fatality of aged cases caused by SARS-CoV-2 was a need to explore the possible age-related phenomena with non-human primate models. Methods: Three 3-5 years old and two 15 years old rhesus macaques were intratracheally infected with SARS-CoV-2, and then analyzed by clinical signs, viral replication, chest X-ray, histopathological changes and immune response. Results: Viral replication of nasopharyngeal swabs, anal swabs and lung in old monkeys was more active than that in young monkeys for 14 days after SARS-CoV-2 challenge. Monkeys developed typical interstitial pneumonia characterized by thickened alveolar septum accompanied with inflammation and edema, notably, old monkeys exhibited diffuse severe interstitial pneumonia. Viral antigens were detected mainly in alveolar epithelial cells and macrophages. Conclusion: SARS-CoV-2 caused more severe interstitial pneumonia in old monkeys than that in young monkeys. Rhesus macaque models infected with SARS-CoV-2 provided insight into the pathogenic mechanism and facilitated the development of vaccines and therapeutics against SARS-CoV-2 infection."],"journal":"Animal Model Exp Med","authors":["Yu, Pin","Qi, Feifei","Xu, Yanfeng","Li, Fengdi","Liu, Peipei","Liu, Jiayi","Bao, Linlin","Deng, Wei","Gao, Hong","Xiang, Zhiguang","Xiao, Chong","Lv, Qi","Gong, Shuran","Liu, Jiangning","Song, Zhiqi","Qu, Yajin","Xue, Jing","Wei, Qiang","Liu, Mingya","Wang, Guanpeng","Wang, Shunyi","Yu, Haisheng","Liu, Xing","Huang, Baoying","Wang, Wenling","Zhao, Li","Wang, Huijuan","Ye, Fei","Zhou, Weimin","Zhen, Wei","Han, Jun","Wu, Guizhen","Jin, Qi","Wang, Jianwei","Tan, Wenjie","Qin, Chuan"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32318665","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ame2.12108","keywords":["sars-cov-2","pathogenicity","pneumonia","rhesus macaque model"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493603020800,"score":435.75412},{"pmid":32054787,"pmcid":"PMC7104368","title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.","text":["Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.","The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV.","Proc Natl Acad Sci U S A","de Wit, Emmie","Feldmann, Friederike","Cronin, Jacqueline","Jordan, Robert","Okumura, Atsushi","Thomas, Tina","Scott, Dana","Cihlar, Tomas","Feldmann, Heinz","32054787"],"abstract":["The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV."],"journal":"Proc Natl Acad Sci U S A","authors":["de Wit, Emmie","Feldmann, Friederike","Cronin, Jacqueline","Jordan, Robert","Okumura, Atsushi","Thomas, Tina","Scott, Dana","Cihlar, Tomas","Feldmann, Heinz"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32054787","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.1073/pnas.1922083117","keywords":["mers-cov","animal model","antiviral","remdesivir","therapy"],"e_drugs":["remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1666138492992749570,"score":307.73587},{"pmid":32361098,"title":"Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis?","text":["Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis?","2019 novel coronavirus (2019-nCoV) is widespread in China and other countries. The target of 2019-nCoV and severe acute respiratory syndrome coronavirus (SARS-CoV) is angiotensin-converting enzyme 2 (ACE2) positive cells. ACE2 is present in the salivary gland duct epithelium, and thus it could be the target of 2019-nCoV and SARS-CoV. SARS-CoV-related animal model experiments show that it can infect the epithelial cells on the salivary gland duct in Chinese rhesus macaques by targeting ACE2. Clinical studies confirmed that 2019-nCoV and SARS-CoV could be detected in saliva of human patients. We hypothesize that the infection of 2019-nCoV and SARS-CoV will lead to inflammatory pathological lesions in patients' target organs, and possibly inflammatory lesions in salivary glands. 2019-nCoV may cause acute sialoadenitis in the acute phase of infection. After the acute phase, chronic sialoadenitis may be caused by fibrosis repairment. Although there was no direct evidence to prove this, the available indirect evidence indicates a high probability of our hypothesis.","Med Hypotheses","Wang, Chenxing","Wu, Heming","Ding, Xu","Ji, Huan","Jiao, Pengfei","Song, Haiyang","Li, Sheng","Du, Hongming","32361098"],"abstract":["2019 novel coronavirus (2019-nCoV) is widespread in China and other countries. The target of 2019-nCoV and severe acute respiratory syndrome coronavirus (SARS-CoV) is angiotensin-converting enzyme 2 (ACE2) positive cells. ACE2 is present in the salivary gland duct epithelium, and thus it could be the target of 2019-nCoV and SARS-CoV. SARS-CoV-related animal model experiments show that it can infect the epithelial cells on the salivary gland duct in Chinese rhesus macaques by targeting ACE2. Clinical studies confirmed that 2019-nCoV and SARS-CoV could be detected in saliva of human patients. We hypothesize that the infection of 2019-nCoV and SARS-CoV will lead to inflammatory pathological lesions in patients' target organs, and possibly inflammatory lesions in salivary glands. 2019-nCoV may cause acute sialoadenitis in the acute phase of infection. After the acute phase, chronic sialoadenitis may be caused by fibrosis repairment. Although there was no direct evidence to prove this, the available indirect evidence indicates a high probability of our hypothesis."],"journal":"Med Hypotheses","authors":["Wang, Chenxing","Wu, Heming","Ding, Xu","Ji, Huan","Jiao, Pengfei","Song, Haiyang","Li, Sheng","Du, Hongming"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361098","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.mehy.2020.109789","keywords":["2019-ncov","angiotensin-converting enzyme 2","clinical character","saliva","sialadenitis"],"locations":["China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138495470534656,"score":293.37802}]}